Tirzepatide
Also known as LY3298176, Mounjaro, Zepbound
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved in some countries for type 2 diabetes and chronic weight management. Large randomized trials have reported substantial average body-weight reduction compared with placebo. It is administered by once-weekly subcutaneous injection with a gradual dose-escalation schedule. As with other incretin-based therapies, individual results vary and long-term studies continue to refine understanding of its effects.
Reported benefits
- Associated with significant average body-weight reduction in clinical trials
- Improves glycemic control in type 2 diabetes
- May improve several cardiometabolic risk markers
- Once-weekly injection schedule
How it works
Tirzepatide activates both GIP and GLP-1 receptors, combining appetite-suppressing and gastric-emptying effects of GLP-1 signaling with additional GIP-receptor activity thought to enhance insulin sensitivity and further support weight reduction. The dual-agonist action is believed to produce greater metabolic effect than GLP-1 agonism alone, though the precise interplay of the two pathways in humans is still being studied.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 2.5 mg | once weekly |
| Moderate | 7.5 mg | once weekly |
| High | 15 mg | once weekly |
Estimate your dose
Dose estimator
Educational estimate for Tirzepatide, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Tirzepatide. Educational only.
Draw to this mark
150units
= 1.5 mL for a 7.5 mg dose
Concentration
5 mg/mL
Doses per vial
1
This dose needs 150 units, more than a 100-unit syringe holds. Add more water, split the dose, or use a larger syringe.
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Combining with other GLP-1/GIP agents is not supported by evidence and may increase side-effect burden; any combination therapy should be supervised by a prescriber.
Common protocols
Common questions
What is Tirzepatide used for?
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved in some countries for type 2 diabetes and chronic weight management. Large randomized trials have reported substantial average body-weight reduction compared with placebo. It is administered by once-weekly subcutaneous injection with a gradual dose-escalation schedule. As with other incretin-based therapies, individual results vary and long-term studies continue to refine understanding of its effects. Reported benefits include associated with significant average body-weight reduction in clinical trials, improves glycemic control in type 2 diabetes, may improve several cardiometabolic risk markers.
What is a typical Tirzepatide dose?
Reported ranges run 2.5-15 mg. A low protocol is 2.5 mg once weekly, and a high protocol is 15 mg once weekly. This is reference information, not a dosing recommendation.
What is the half life of Tirzepatide?
Approximately 5 days, supporting once-weekly dosing. That is what sets the dosing frequency, and it is why the timing guidance is weekly · same day, any time.
How is Tirzepatide administered?
Subcutaneous: into fat, under the skin.
How long is a Tirzepatide cycle?
Continuous, ongoing use with titration per prescriber guidance on, followed by Not typically cycled off; any discontinuation should be discussed with a prescriber off. Weight regain has been observed after discontinuation in published follow-up data.
What are the side effects of Tirzepatide?
Reported side effects include nausea, vomiting, diarrhea, and constipation, particularly during titration, decreased appetite, risk of gallbladder-related events, injection-site reactions, class-labeled theoretical thyroid c-cell tumor risk. Evidence level for this compound is well studied.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Tirzepatide may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →